GLOBALT Investments LLC GA Sells 8,613 Shares of Stryker Corporation $SYK

GLOBALT Investments LLC GA reduced its stake in Stryker Corporation (NYSE:SYK) by 47.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,397 shares of the medical technology company’s stock after selling 8,613 shares during the period. GLOBALT Investments LLC GA’s holdings in Stryker were worth $3,303,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the stock. Intrua Financial LLC boosted its position in shares of Stryker by 24.5% in the fourth quarter. Intrua Financial LLC now owns 1,415 shares of the medical technology company’s stock valued at $497,000 after acquiring an additional 278 shares during the period. Odyssey Capital Advisors Inc. bought a new stake in Stryker during the fourth quarter valued at $656,000. Peak Asset Management LLC lifted its position in Stryker by 0.7% during the fourth quarter. Peak Asset Management LLC now owns 49,224 shares of the medical technology company’s stock valued at $17,301,000 after purchasing an additional 350 shares during the last quarter. Tucker Asset Management LLC bought a new stake in Stryker during the fourth quarter valued at approximately $40,000. Finally, Requisite Capital Management LLC lifted its position in Stryker by 67.1% during the fourth quarter. Requisite Capital Management LLC now owns 1,165 shares of the medical technology company’s stock valued at $410,000 after purchasing an additional 468 shares during the last quarter. 77.09% of the stock is owned by institutional investors.

Insider Buying and Selling at Stryker

In other news, VP M Kathryn Fink sold 5,220 shares of the company’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $283.85, for a total value of $1,481,697.00. Following the completion of the transaction, the vice president owned 13,137 shares of the company’s stock, valued at $3,728,937.45. This represents a 28.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 4.60% of the stock is currently owned by insiders.

Stryker Stock Down 0.0%

Stryker stock opened at $306.74 on Monday. The stock has a fifty day simple moving average of $329.68 and a two-hundred day simple moving average of $351.50. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $404.87. The firm has a market cap of $117.59 billion, a price-to-earnings ratio of 35.50, a PEG ratio of 1.93 and a beta of 0.80. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.38). The firm had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $6.34 billion. Stryker had a return on equity of 23.42% and a net margin of 13.20%.The business’s revenue was up 2.6% on a year-over-year basis. During the same period in the previous year, the firm earned $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Equities analysts predict that Stryker Corporation will post 14.98 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date is Tuesday, June 30th. Stryker’s dividend payout ratio is presently 40.74%.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on SYK. Robert W. Baird set a $385.00 price objective on shares of Stryker in a report on Friday, May 1st. Piper Sandler reissued an “overweight” rating on shares of Stryker in a research note on Tuesday, January 27th. Wells Fargo & Company lowered their price target on shares of Stryker from $456.00 to $418.00 and set an “overweight” rating for the company in a report on Friday, May 1st. BTIG Research lowered their price target on Stryker from $397.00 to $379.00 and set a “buy” rating for the company in a research report on Friday, May 1st. Finally, Evercore set a $355.00 price target on Stryker in a research report on Friday, May 1st. Sixteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $395.48.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.